15:53 , Jul 3, 2019 |  BioCentury  |  Emerging Company Profile

Kymera: a systematic approach to protein degradation

With a computational drug discovery platform and a proprietary library of E3 ligases and binders, Kymera believes it can accelerate the discovery and development of protein degraders. Protein degradation is entering the mainstream as a...
19:55 , Apr 11, 2019 |  BC Innovations  |  Emerging Company Profile

Nurix: Two sides of protein degradation

Nurix is flipping the concept of targeted protein degradation on its head. In addition to the usual approach of inducing target destruction, the company has technology that can block E3 ligase activity and increase a...
11:17 , Apr 24, 2018 |  BC Extra  |  Financial News

Protein stability play Cedilla launches with $56.2M series A

Third Rock Ventures launched Cedilla Therapeutics Inc. (Cambridge, Mass.) with a tranched $56.2 million series A round. Details regarding the tranches were not disclosed. Cedilla is developing small molecules that target processes upstream of the...
11:12 , Apr 24, 2018 |  BioCentury  |  Finance

Protein player

By modulating targets upstream of the ubiquitin proteasome system and inducing both stabilization and destabilization of target proteins, Third Rock Ventures believes newco Cedilla Therapeutics Inc. could have a broader reach than competing protein degradation...